CoreCap Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

CoreCap Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-24	Closed	-$1.01K	–	3154
2026 Q2	$1.01K	Buy	+24	New	+$764	﹤0.01%	2692
2026 Q1	–	Sell	-16	Closed	-$464	–	2944
2025 Q4	$464	Sell	16 -37	-70%	-$1.11K	﹤0.01%	2715
2025 Q3	$1.47K	Hold	53	–	–	﹤0.01%	2428
2025 Q2	$1.29K	Hold	53	–	–	﹤0.01%	2386
2025 Q1	$1.1K	Hold	53	–	–	﹤0.01%	2502
2024 Q4	$1.25K	Hold	53	–	–	﹤0.01%	2332
2024 Q3	$1.36K	Hold	53	–	–	﹤0.01%	2228
2024 Q2	$1.24K	Sell	53 -51	-49%	-$1.29K	﹤0.01%	1375
2024 Q1	$2.99K	Buy	+104	New	+$3.13K	﹤0.01%	2036
2022 Q4	$3.39K	Buy	+120	New	+$3.81K	﹤0.01%	1839
2022 Q3	–	Sell	-252	Closed	-$8K	–	626
2022 Q2	$8K	Buy	+252	New	+$8.81K	﹤0.01%	1526
2022 Q1	–	Sell	-252	Closed	-$15K	–	636
2021 Q4	$15K	Buy	+252	New	+$17.4K	﹤0.01%	1404

Other funds holding ARKG

MFPI

Midwest Financial Partners Investments St. Cloud, Minnesota $260M AUM 10.89% 1-Year Est. Return

CFIM

Client First Investment Management West Bend, Wisconsin $210M AUM 50.85% 1-Year Est. Return

PRTG

Post Resch Tallon Group Pittsford, New York $146M AUM 18.19% 1-Year Est. Return

TAM

Titleist Asset Management San Antonio, Texas $1.55B AUM 13.34% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GWM

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

MHR

Matthew Hamilton Rosenberg $558M AUM 12.28% 1-Year Est. Return

AAG

Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return

CoreCap Advisors's ARKG Position: Q3 2026 in Review

CoreCap Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2026, closing a stake of 24 shares — an estimated $1.01K sold.

CoreCap Advisors first reported a position in ARKG in Q4 2021 and held it in 12 quarters. The position peaked at $15K in Q4 2021. 8 funds tracked by Wall St. Rank hold ARKG as of Q3 2026.

CoreCap Advisors reported no remaining ARK Genomic Revolution ETF position as of Q3 2026 after selling out during the quarter.
CoreCap Advisors sold 24 ARK Genomic Revolution ETF shares in Q3 2026, an estimated $1.01K.
CoreCap Advisors first reported a position in ARK Genomic Revolution ETF in Q4 2021 and held it in 12 quarters.
CoreCap Advisors's ARK Genomic Revolution ETF position peaked at $15K in Q4 2021.
8 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.